Radical cystectomy in the treatment of bladder cancer in Iceland: A population-based study

Abstract

Objective: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer. Postoperative complications are reported to be as high as 65%. The objective of this study was to investigate complications and survival in Icelandic patients with bladder cancer who underwent RC. Materials and methods: All patients who had bladder cancer and underwent RC in Iceland from 2003 to 2012 were included. Information was obtained retrospectively from patients’ medical records and from the Icelandic Cause of Death Registry. Complications were classified according to the Clavien–Dindo classification system. The Kaplan–Meier method was used in the survival analysis. Only patients with transitional cell carcinoma (TCC) were included in the survival analysis. Results: Overall, 108 patients (male 81%, median age 68 years) underwent the procedure during the study period and 100 of them had TCC. Ileal conduit was performed in 86% of procedures and orthotopic neobladder in 14%. The median operation time was 266 min and the median blood loss during the procedure was 1000 ml. No patient died within 30 days of surgery, but one patient (0.9%) died within 90 days of surgery from complications of the surgery. Complications were reported for 62 patients (57%) overall. Major complications (Clavien 3–5) were reported in 32 patients (29%), and 30 patients (28%) had only minor complications (Clavien 1–2). Twenty-four patients (22%) had to undergo reoperation. Overall 5 year survival was 54%. Conclusion: Morbidity after RC is high but similar to that seen in other studies. Long-term survival of Icelandic patients is comparable to that in neighboring countries.

Keywords: :

• Bladder cancer
• complications
• radical cystectomy
• survival

Funding: No grants were received for this study.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.